UNSPSC 51384700: Nonsteroidal anti inflammatory pyridazines

Nonsteroidal anti inflammatory drugs made from orthodiazines, compounds consistng of six-membered ring with two adjacent nitrogen atoms.

UNSPSC 51384700 Nonsteroidal anti inflammatory pyridazines is a Class code that sits misaligned with the recent state and local solicitations tagged to it. The code nominally describes a specific pharmaceutical compound class, but the recent opportunities under this code—Naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements—fall outside that narrow scope and instead reflect state and local buying of a much broader range of pharmaceutical products, over-the-counter items, and specialty drug-fulfillment services. The issuing bodies are state health agencies (Texas Health and Human Services Commission), cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions), and county public health departments (Seminole County, Florida). This suggests the code is being used as a catch-all for pharmaceutical procurement rather than as a precise match to the product family.

Recent activity is spread across Texas, Minnesota, Oregon, and Florida. The Texas HHS Commission posted a Request for Information (RFI) on April 3, 2026, to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP due March 26, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with pricing weighted at 75 percent of evaluation and awards effective July 1, 2026. Seminole County, Florida released an Invitation for Bid (IFB) numbered IFB60459723LAS on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, a response deadline of July 26, 2023, and a two-year initial term with optional one-year renewal. The code shows activity but little recent opportunity volume; the mismatch between the nominal code definition and actual procurement scope signals that this UNSPSC classification may not reliably surface relevant opportunities for pharmaceutical vendors targeting state and local health agencies.